Systemic therapies for pancreatic cancer--the role of pharmacogenetics.
Systemic therapies for pancreatic cancer--the role of pharmacogenetics.
复制标题
DOI：
10.2174/138945012800564068
复制
发表时间：
2012-06
影响因子：
3.2
通讯作者：
Innocenti F
中科院分区：
文献类型：
--
作者：
Soo RA;Yong WP;Innocenti F
胰腺癌的有效全身治疗仍然是一个重大挑战，其进展受到耐药性和治疗相关毒性的阻碍。目前可用的细胞毒性药物作为单药治疗或联合治疗仅为晚期疾病患者提供了适度的生存获益。吉西他滨联合治疗晚期胰腺癌患者的III期结果令人失望，可能与胰腺癌患者全身治疗的疗效差有关。未来的研究策略应优先通过药物遗传学研究确定预测标志物。通过药物遗传学对患者进行个体化治疗，可能有助于通过最大限度地提高疗效同时降低毒性来改善结局。本文综述了胰腺癌治疗的药物遗传学及其对治疗获益和毒性的影响。
Effective systemic treatment of pancreatic cancer remains a major challenge, with progress hampered by drug resistance and treatment related toxicities. Currently available cytotoxic agents as monotherapy or in combination have provided only a modest survival benefit for patients with advanced disease. Disappointing phase III results with gemcitabine-based combinations in patients with advanced pancreatic cancer might be related to poor efficacy of systemic therapies in unselected patients. Future research strategies should prioritize identification of predictive markers through pharmacogenetic investigations. The individualization of patient treatment through pharmacogenetics may help to improve outcome by maximizing efficacy whilst lowering toxicity. This review provides an update on the pharmacogenetics of pancreatic cancer treatment and its influence on treatment benefits and toxicity.